- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
September 16th, 2004
Biophan Technologies, Inc., a developer of next-generation biomedical technology, has appointed biotechnology executive John Lanzafame to serve as president of the Company's Nanolution division, according to Biophan CEO Michael Weiner.
As Nanolution president, Mr. Lanzafame will oversee Biophan's development of advanced nanotechnology-based drug delivery devices and drug-elution technologies, patents, and products.
|Related News Press|
Simple attraction: Researchers control protein release from nanoparticles without encapsulation: U of T Engineering discovery stands to improve reliability and fabrication process for treatments to conditions such as spinal cord damage and stroke May 28th, 2016
Doubling down on Schrödinger's cat May 27th, 2016